Immunocore Holdings (IMCR) EBIT (2023 - 2026)

Immunocore Holdings has disclosed EBIT across 4 years of filings, most recently posting $7.3 million for Q1 2026.

• EBIT for Q1 2026 came in at $7.3 million, up 301.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$34.5 million (up 27.59% YoY), and the FY2025 annual result was -$45.4 million, up 35.63% from the prior year.
• EBIT came in at $7.3 million for Q1 2026 at Immunocore Holdings, up from -$19.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $7.3 million in Q1 2026 to a low of -$26.5 million in Q1 2024.
• The 4-year median for EBIT is -$14.7 million (2023), against an average of -$12.9 million.
• Across the five-year window, EBIT tumbled 80.25% in 2024 and surged 301.33% in 2026, its largest moves.
• Immunocore Holdings' EBIT stood at -$17.1 million in 2023, then declined by 14.07% to -$19.5 million in 2024, then declined by 1.23% to -$19.7 million in 2025, then soared by 136.97% to $7.3 million in 2026.
• The last three EBIT figures came in at $7.3 million (Q1 2026), -$19.7 million (Q4 2025), and -$7.2 million (Q3 2025), per Business Quant data.